Promus Capital LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Promus Capital LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $66,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Swedbank AB grew its holdings in Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares in the last quarter. Moloney Securities Asset Management LLC raised its position in Pfizer by 37.8% during the 3rd quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock worth $610,000 after buying an additional 5,785 shares during the last quarter. Cary Street Partners Asset Management LLC raised its position in Pfizer by 7.0% during the 3rd quarter. Cary Street Partners Asset Management LLC now owns 18,865 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 1,238 shares during the last quarter. Hanlon Investment Management Inc. purchased a new position in shares of Pfizer during the 3rd quarter valued at approximately $205,000. Finally, NorthRock Partners LLC increased its holdings in shares of Pfizer by 2.0% during the 3rd quarter. NorthRock Partners LLC now owns 25,102 shares of the biopharmaceutical company’s stock valued at $726,000 after purchasing an additional 497 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.7 %

NYSE:PFE opened at $25.93 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business has a 50 day simple moving average of $26.31 and a 200 day simple moving average of $27.27. The firm has a market capitalization of $146.93 billion, a P/E ratio of 18.39, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The company’s revenue was up 24.7% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.63%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is currently 121.99%.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim reissued a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.